HCA Healthcare management check

HCA · Health Care · Health Care Facilities · CEO Hazen

Filings as of

90
Management score, ranked 8th of 487Strongest: owner returns. Weakest: pay for performance. See the best and worst run in Health Care →

6 good · 0 to watch · 0 flagged, across the seven questions below.

  • Good

    Have owners done well?

    Beat its chosen peers

    $100 invested at the start of fiscal 2021 grew to $296, against $148 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.52 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.4% of net income

    $26.5m of reported pay in fiscal 2025, against $6.8bn of net income.

  • n/a

    Do they own the stock?

    No recent CEO filing

    No open-market insider buying or selling in the last six months.

  • Good

    Are owners being diluted?

    Share count shrinking

    Diluted shares changed -6.9% a year over the last three fiscal years. Stock-based pay was 0.5% of revenue in the latest year.

  • Good

    Is leadership stable?

    9 leadership filings in 3 years

    CEO in the pay table: Hazen. 9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    No restatements, auditor changes or late filings since 2021.

Against the S&P 500

Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.

CheckScoreAt or aboveSector median
Owner returns100100%26
Pay for performance7638%85
CEO cost8483%44
Skin in the game——46
Dilution100100%68
Stable leadership8056%70
Clean books100100%100

Closest peers

Others in Health Care Facilities, by management score. HCA Healthcare is 1st of 60 in its sector.

  1. 8HCAHCA Healthcare90
  2. 19VRTXVertex Pharmaceuticals86
  3. 32LLYLilly (Eli)84
  4. 43GILDGilead Sciences82
  5. 45CAHCardinal Health81
  6. 59UHSUniversal Health Services79

Pay versus performance

From the proxy statement filed March 13, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.

CEO pay by fiscal yearAs reported Actually paid
$0$42.3m$84.6m20212022202320242025
What $100 becameCompany Peer group
$10020212022202320242025$296
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Hazen$26.5m$78.2m$8.2m$296$148$6.8bn
2024—$23.8m$40.1m$6.1m$189$129$5.8bn
2023—$21.3m$23.6m$6.9m$169$126$5.2bn
2022—$14.6m$9.6m$5.2m$149$124$5.6bn
2021—$20.6m$84.6m$6.0m$158$126$7.0bn

The board says pay is tied most to Adjusted EBITDA. Its other key measures: Earnings Per Share, Quality of Care, Patient Experience.

Insiders and the CEO's stake

No open-market insider buying or selling in the last six months.

Leadership and governance on file

Latest shareholder vote results: Apr 28, 2026, including the say-on-pay vote.

Where the money went

Over 2021–2025: $38.4bn returned to owners in buybacks and dividends, 127% of net income, and $1.8bn of pay in stock.

Fiscal year20212022202320242025
Revenue$58.8bn$60.2bn$65.0bn$70.6bn$75.6bn
Net income$7.0bn$5.6bn$5.2bn$5.8bn$6.8bn
Stock-based pay$440.0m$341.0m$262.0m$360.0m$401.0m
Buybacks$8.2bn$7.0bn$3.8bn$6.0bn$10.1bn
Dividends$624.0m$653.0m$661.0m$690.0m$679.0m
Diluted shares329m295m276m262m239m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.